Made by Japanese pharmaceutical firm Shionogi, ensitrelvir is approved in Japan for the treatment of mild to moderate ...

Hospital researchers say the observed increase in clinical cases of the multidrug-resistant fungus mirrors national trends.

On average over four seasons, the study found that RSV caused 84.7 hospitalizations per 100,000 among people older than 60 years, and varied significantly depending on age and certain risk factors.

1 Day SGIOY -2.62% DJIA 1.39% S&P 500 1.59% Health Care/Life Sciences -0.37% ...

However, Louisiana had both an earlier and higher trend in respiratory viruses this season, with high flu, COVID and RSV activity in early December. "We've had more overall activity because high ...

Maze has also licensed out MZE001, a treatment for Pompe disease, to Shionogi. While not rated by Leerink, the licensing of MZE001 indicates the breadth of Maze's drug development platform.

Pediatric RSV treatment itself is expected to be a multi ... peramivir (Rapivab®, Biocryst), and baloxavir (Xofluza®, Shionogi/Roche). Additionally, NV-387 also demonstrated activity against ...

Pediatric RSV treatment itself is expected to be a multi ... peramivir (Rapivab®, Biocryst), and baloxavir (Xofluza®, Shionogi/Roche). Additionally, NV-387 also demonstrated activity against ...